According to clinical and preclinical studies, does copper tripeptide actually work?

Copper tripeptide demonstrates repeatable biological activity in preclinical research and a limited number of human studies, particularly in areas such as skin regeneration, wound healing, and tissue remodelling. However, the strength of the evidence varies depending on the specific application and remains limited for systemic effects. In vitro and animal studies indicate that copper peptide enhances collagen production, supports angiogenesis, regulates repair-related genes, and accelerates wound closure. These findings support its influence on regenerative processes and tissue rebuilding [1,2]. Improvements in extracellular matrix formation and reduced tissue damage under stress conditions have also been observed in many experimental models.

Human study data are available, but mainly concern topical applications. Clinical trials using copper peptide-containing preparations demonstrate improvement in skin quality, including increased thickness, better elasticity, and reduced wrinkle visibility over an 8–12 week period [3,4]. In wound treatment, including diabetic ulcers, controlled studies have shown faster healing compared to standard methods, indicating its effect on local tissue regeneration [5]. However, it should be emphasised that most studies involve small groups and focus on the skin or superficial tissues, rather than systemic effects.

From a mechanistic standpoint, copper peptide acts as a signalling molecule. This means it regulates biological processes such as gene expression, growth factor production, and antioxidant mechanisms, rather than acting like a classic drug requiring high doses. This explains why effects are observed at relatively low concentrations under controlled conditions. Copper peptide used in research is available through suppliers such as SemaxPolska. While current data support its biological activity, they do not constitute proof of broad clinical efficacy in all applications, especially in the context of systemic action.

What clinical trials in humans concern copper peptide and what are their results?

Clinical trials involving humans focusing on copper peptide primarily concentrate on skin and wound healing, with their results indicating measurable improvements in tissue regeneration and skin condition. One of the most well-known controlled studies included patients with diabetic ulcers and demonstrated significantly faster healing compared to standard treatment, confirming its role in the regeneration of damaged skin [5].

In cosmetic dermatology, both placebo-controlled and open-label studies have been conducted using copper peptide creams over several weeks. These studies demonstrated an increase in skin thickness, improved elasticity, a reduction in fine wrinkles, and an overall improvement in skin appearance [3,4]. Some studies involving dozens of participants observed changes in skin structure, indicating an effect on dermal remodelling. Additional research on UV-damaged skin and regeneration after dermatological procedures also showed improved healing and reduced visible damage following topical application [6].

Despite these results, there are significant limitations. The number of large, well-designed, multi-centre clinical trials remains small. Most studies focus on topical applications, and high-quality data regarding other routes of administration, such as oral, injectable or nasal in humans, are limited. Present clinical data confirm its efficacy within the skin but do not support broad medical applications across various conditions.

The areas of research into copper tripeptide where the strongest evidence exists are wound healing and skin anti-aging.

The strongest evidence pertains to the action of copper tripeptide in skin regeneration, wound healing, and the regulation of cellular repair processes. Wound healing is one of the best-documented areas. Studies show faster tissue regeneration, increased collagen deposition, improved blood vessel formation, and more effective wound closure in various experimental models [2, 7]. Clinical trial results concerning diabetic ulcers further confirm these observations [5].

Another well-documented area is skin aging and cosmetic dermatology. Numerous studies demonstrate that copper peptide improves skin structure, increases collagen and elastin production, and reduces visible signs of aging. These effects have been confirmed in controlled clinical trials, which documented improvements in skin thickness, elasticity, and appearance [3]. Gene expression studies also indicate that copper peptide influences many genes related to repair, inflammation control, and antioxidant protection, highlighting its role as a regulator of biological processes [8].

Other areas, such as neuroprotection, anti-inflammatory action, or general tissue regeneration, are still under development. Although preclinical studies indicate promising results, confirmation in human clinical trials is limited. The copper peptide used in studies is available through suppliers like SemaxPolska. Currently, the strongest evidence relates to dermal applications and local tissue regeneration, and laboratory and animal study results should not be directly extrapolated to broad clinical applications without further research.

References

1. Pickart, L. (2008). The human tri-peptide GHK and tissue remodelling. Journal of Biomaterials Science, Polymer Edition, 19(8), 969–988.
2. Siméon, A., Monier, F., Emonard, H., Gillery, P., & Maquart, F. X. (1999). Expression and activation of matrix metalloproteinases in wounds: Modulation by the tripeptide–copper complex glycyl-L-histidyl-L-lysine-Cu2+. Journal of Investigative Dermatology, 112(6), 957–964.
3. Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data. International Journal of Molecular Sciences, 19(7), 1987.
4. Badenhorst, T., Svirskis, D., Merrilees, M., & Bolke, L. (2016). Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science, 4(2), 1–8.
5. Mulder, G. D., Patt, L. M., Sanders, L., Rosenstock, J., Altman, M. I., Hanley, M. E., & Duncan, G. W. (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration, 2(4), 259–269.
6. Miller, T. R., Wagner, J. D., Baack, B. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser–resurfaced skin. Archives of Facial Plastic Surgery, 8(4), 239–243.
7. Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., & Zhang, L. (2017). GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration, 25(2), 280–287.
8. Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2015). GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics, 2(3), 236–247.